Key result
Deleting Kdm5a improves cardiac function and survival in LMNA cardiomyopathy mice, restoring ~1,400 dysregulated genes.
Why the study?
KDM5A is reactivated in failing human and mouse hearts, but its pathogenic role in heart failure remained unknown.
Does deletion of the Kdm5a gene improve cardiac function and survival in a mouse model of LMNA-cardiomyopathy?
Does deletion of the Kdm5a gene improve cardiac function and survival in a mouse model of LMNA-cardiomyopathy?
Deletion of the epigenetic regulator KDM5A improves cardiac function and survival in a mouse model of LMNA-cardiomyopathy, identifying it as a potential therapeutic target in heart failure.
KDM5A emerges as a candidate target in LMNA-cardiomyopathy; hypothesis-generating in this animal model and requires human validation.
Heart failure is a complex disease characterized by the dysregulation of gene expression that culminates in cardiac dysfunction. Epigenetic regulators play a critical role in control of transcription and are increasingly implicated in the pathogenesis of heart failure. We recently showed that the histone demethylase KDM5A is reactivated in the heart of human patients and mouse models of heart failure. However, its pathogenic role in heart failure remained unknown. Utilizing a mouse model of heart failure caused by the deletion of the Lmna gene in cardiomyocytes and referred to as LMNA-cardiomyopathy (LMNA-CMP), we show that KDM5A is activated, and expression levels of genes involved in myocyte structure and function, including oxidative phosphorylation (OXPHOS), are suppressed. To determine the pathogenic role of KDM5A in heart failure, the Kdm5a gene was specifically deleted in cardiomyocytes in LMNA-CMP mice ( Myh6-Cre:Lmna F/F : Kdm5a F/F ). The deletion of the Kdm5a gene improved cardiac function, prolonged survival, attenuated fibrosis, and reduced cell death in LMNA-CMP mice. Transcriptome analysis showed that the deletion of the Kdm5a gene restored the expression of over 1,400 dysregulated genes, including those involved in fatty acid metabolism, myogenesis, and OXPHOS in the Myh6-Cre:Lmna F/F : Kdm5a F/F mice. Genome-wide profiling of the epigenetic histone mark H3 lysine 4 trimethylation (H3K4me3), the main target of KDM5A, by CUT&RUN assay showed that deletion of the Kdm5a gene partially restored H3K4me3 deposits at loci encoding cardiac transcription factors and metabolic regulators, including Tbx5 and Esrrg , with concomitant rescue of their downstream targets. These findings identify KDM5A as a key epigenetic regulator of cardiomyocyte gene expression and uncover a mechanistic role for KDM5A in the pathogenesis of heart failure.
No takes yet. Share an insight, caveat, or question.
Deogharia et al. (2026) studied Heart failure (LMNA-cardiomyopathy). Cardiomyocyte-specific deletion of the Kdm5a gene vs. LMNA-CMP mice without Kdm5a deletion was evaluated on Cardiac function, survival, fibrosis, and cell death. Cardiomyocyte-specific deletion of the Kdm5a gene in LMNA-cardiomyopathy mice improved cardiac function, prolonged survival, and restored the expression of over 1,400 dysregulated genes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: